Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia

Pediatric Infectious Disease Journal

Volumn 31, Issue 6, 2012, Pages 630-632

  Undre, Nasrullah A ^a   Stevenson, Paul ^b   Freire, Antonio ^c   Arrieta, Antonio ^d  

^a ASTELLAS PHARMA EUROPE LTD   (United Kingdom)

^b Formerly of Astellas Pharma GmbH   (Germany)

^c Hospital Santa Casa de Misericórdia de Belo Horizonte   (Brazil)

^d CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Candidemia; Micafungin; Pediatrics; Pharmacokinetics

Indexed keywords

DRUG METABOLITE; MICAFUNGIN;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANDIDEMIA; CHILDHOOD DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; INVASIVE CANDIDIASIS; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; AGE FACTORS; ANTIFUNGAL AGENTS; CANDIDEMIA; CANDIDIASIS, INVASIVE; CHILD; CHILD, PRESCHOOL; ECHINOCANDINS; FEMALE; HUMANS; INFANT; LIPOPEPTIDES; MALE; METABOLIC CLEARANCE RATE;

EID: 84861531997     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31824ab9b0     Document Type: Article

References (9)

1. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46:150-156.
2. Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther. 2010;87:93-99.
3. Tabata K, Katashima M, Kawamura A, et al. Pharmacokinetics- pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis. Eur J Drug Metab Pharmacokinet. 2006;31:123-128.
4. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005;49:3317-3324.
5. Kuse ER, Chetchotisakd P, da Cunha CA, et al.; Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519-1527.
6. Yamato Y, Kaneko H, Tanimoto K, et al. Simultaneous determination of antifungal drug, micafungin, and its two active metabolites in human plasma using high-performance liquid chromatography with fluorescence detection. Jpn J Chemother. 2002;50(suppl 1):68-73.
7. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis. 2008;197:163-171.
8. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28: 412-415.
9. Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54:2633-2637.